Pentoxifylline added to usual skin treatment for mild-to-moderate plaque psoriasis
Tests pentoxifylline alongside usual skin treatment in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
Key facts
- Where
- Phayao, ThailandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07626788, who can take part
Where in Thailand
- University of Phayao HospitalPhayao, ThailandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wasuchon Chaichan
- Trial code
- NCT07626788
- Record updated
- 6 October 2026
- Original description
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.Read full original descriptionShow less
Efficacy and Safety of Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis: A Double-Blind Randomized Placebo-Controlled Trial
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.
Inclusion: Adults aged 18 to 65 years; Clinical diagnosis of mild-to-moderate plaque psoriasis, defined as Psoriasis Area and Severity Index (PASI) score 3 to 10 or body surface area (BSA) involvement 3% to 10%, as assessed by a physician; Receiving stable standard topical therapy for at least 2 weeks before enrollment; Able and willing to provide written informed consent; Willing to comply with the study protocol and scheduled follow-up visits.
Exclusion: Use of biologic agents within 12 weeks before enrollment; Psoriatic arthritis requiring systemic therapy; Severe liver disease or severe kidney disease; History of significant bleeding disorder or current use of anticoagulant therapy that cannot be appropriately managed; Known hypersensitivity to pentoxifylline or related xanthine derivatives; Any serious medical condition or safety concern that, in the investigator's judgment, makes participation inappropriate; Pregnant or breastfeeding; Refusal or inability to provide informed consent.